APM
RVMD icon

Avidity Partners Management’s Revolution Medicines RVMD Stock Holding History

Avidity Partners Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.46M Buy
+15,000
New +$1.51M 0.16% 42
2025
Q3 		– Sell
-228,600
Closed -$8.41M – 60
2025
Q2 		$8.41M Buy
228,600
+15,600
+7% +$599K 1.68% 23
2025
Q1 		$7.53M Sell
213,000
-233,200
-52% -$9.47M 1.44% 28
2024
Q4 		$19.5M Sell
446,200
-343,800
-44% -$17.4M 1.92% 23
2024
Q3 		$35.8M Buy
790,000
+35,000
+5% +$1.52M 1.83% 22
2024
Q2 		$29.3M Buy
755,000
+120,000
+19% +$4.49M 1.25% 33
2024
Q1 		$20.5M Buy
635,000
+575,000
+958% +$17M 0.66% 50
2023
Q4 		$1.72M Sell
60,000
-597,200
-91% -$14.4M 0.06% 70
2023
Q3 		$18.2M Sell
657,200
-417,800
-39% -$12.4M 0.73% 50
2023
Q2 		$28.8M Sell
1,075,000
-269,800
-20% -$6.62M 1% 40
2023
Q1 		$29.1M Sell
1,344,800
-1,130,200
-46% -$27.8M 0.97% 38
2022
Q4 		$59M Buy
2,475,000
+153,800
+7% +$3.27M 1.28% 27
2022
Q3 		$45.8M Buy
2,321,200
+996,200
+75% +$21.9M 0.93% 36
2022
Q2 		$25.8M Buy
+1,325,000
New +$25.8M 0.59% 37

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Avidity Partners Management's RVMD Position: Q1 2026 in Review

Avidity Partners Management opened a new position in Revolution Medicines (RVMD) in Q1 2026: 15,000 shares worth $1.46M. The stake represents 0.16% of the portfolio and ranks #42 among its holdings. This is a return to the name: Avidity Partners Management previously reported a position in RVMD as recently as Q2 2025.

Avidity Partners Management first reported a position in RVMD in Q2 2022 and has held it in 14 quarters since. The position peaked at $59M in Q4 2022. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • Avidity Partners Management held 15,000 shares of Revolution Medicines worth $1.46M as of Q1 2026.
  • Revolution Medicines was a new Avidity Partners Management position in Q1 2026.
  • Revolution Medicines made up 0.16% of Avidity Partners Management's portfolio in Q1 2026, its #42 holding.
  • Avidity Partners Management first reported a position in Revolution Medicines in Q2 2022 and has held it in 14 quarters since.
  • Avidity Partners Management's Revolution Medicines position peaked at $59M in Q4 2022.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Avidity Partners Management's 13F filing for Q1 2026, filed 13 May 2026.